Medicine Recommendations

Treating moderate to severe atopic dermatitis - NICE TA814

NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

Non-Neurogenic Bowel Disorders, Chronic Constipation or Chronic Faecal Incontinence

Peristeen transanal irrigation system for managing bowel dysfunction (MTG36)

Neurogenic Bowel Dysfunction

Peristeen transanal irrigation system for managing bowel dysfunction (MTG36)

Depressive illness

Vaccination (travel)

N/A

Depressive illness

Acute Gout (as per LSCMMG Guidelines)

Insomnia (short term use)

For the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.

Schizophrenia and other psychoses, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour, severe anxiety

Drug induced extrapyramidal side effects

Asthma

Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2-agonist

COPD

Depressive illness

a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.

Restriction: Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.

Hospital specialist initiation only for long term severe and disabling depressive illness, after trial of standard antidepressant treatment and as an adjunct to other antidepressant medication

Except for mitochondrial disorders

Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed.

MHRA Aug 2018 Update - Ulipristal

Drug Safety Update March 2020 - Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury